Study Published in Nature Digital Medicine Shows Potential of Machine Learning and Augmented Reality-based Digital Biomarkers in Alzheimer’s Detection
October 19, 2023 08:00 AM Eastern Daylight Time
WASHINGTON--(BUSINESS WIRE)--Altoida, a pioneer in developing digital biomarkers of neurological disease using augmented reality and machine learning, announced today it will be presenting poster presentations at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held in Boston and online, October 24-27, 2023.
“We look forward to presenting new data at CTAD 2023, that highlight Altoida’s latest research. Our presented data exemplifies our commitment to advancing the field of Alzheimer’s disease through cutting-edge technology and data-driven insights”Tweet this
"We look forward to presenting new data at CTAD 2023, that highlight Altoida’s latest research. Our presented data exemplifies our commitment to advancing the field of Alzheimer’s disease through cutting-edge technology and data-driven insights," said Marc Jones, CEO of Altoida. "Digital biomarkers have the potential to revolutionize our understanding of Alzheimer's and transform research, clinical trials, and patient diagnosis and treatment. We eagerly anticipate collaborative efforts with our partners in early disease detection and treatment."
Details of the poster presentations are below:
Poster Title: Correlation between Altoida’s digital cognitive assessment and standard neuropsychological tests in individuals with mild cognitive impairment and cognitively healthy volunteers
Poster Number: P189
Date/Time: Friday, October 27, 8 am to 5 pm
Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida
Poster Title: Building an Evidence Library of Digital Measurement Technologies to Accelerate Endpoint Development in Alzheimer’s Disease and Related Dementias Clinical Trials
Poster Number: P190
Date/Time: Friday, October 27, 8 am to 5 pm
Presenter: Emmanuel Streel, Ph.D., Sr. Medical Affairs Director, Altoida
About Altoida
Altoida is a pioneer in developing digital biomarkers of neurological conditions using augmented reality and machine learning. Our technology platform is designed to enable an objective evaluation of an individual’s cognitive health, which may potentially allow for faster patient selection for clinical trials, as well as sensitive monitoring of disease progression and treatment response. Altoida’s mission is to enable a new era of precision neurology using digital biomarkers. Our proprietary evidence-based platform is founded on more than 20 years of scientific research and published in multiple peer-reviewed papers including Nature Digital Medicine. For more information, visit www.altoida.com. Follow us on Twitter @altoida.
Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com
